Inhibrx Biosciences, Inc.

INBX
$101.32 (- $9.25 - 8.37%)
Last updated: 2026-05-24 18:08 UTC
INBX Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS45720L1070
CUSIP45720L107
Market Price101.32
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-11.96
Market Cap$1.2B
Book Value2.54
Price to Book31.638
BetaN/A
52w High94.56
52w Low10.8
Next Earnings DateN/A

Inhibrx Biosciences, Inc. trades under ticker INBX on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US45720L1070, CUSIP 45720L107. Also searched as Inhibrx Biosciences.

Related researchINBX stock priceINBX share price45720L107Inhibrx Biosciences stockInhibrx Biosciences share price
About the Company
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Price History